ABA Emerging Issues in Healthcare Law Conference

American Bar Association Health Law Section

Alyson Wooten discussed “Experimental Medicine: The FDA’s Role, Litigation, and Risk Management Trends” on April 28. Healthcare consumers often demand access to and coverage for experimental and investigational treatments for serious and terminal illnesses. This session covered trends in Food and Drug Administration (FDA) approval, litigation, and risk management, including the FDA approval process, experimental medicine trends during the COVID-19 pandemic, ivermectin and similar litigation, and the role of courts in setting the standard of care for providers or medical necessity standards for insurers. The session also covered risk management tips for hospital systems and other providers.

Find out more. BRG was a sponsor.